There are currently no upcoming events.

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Physicians Throughout U.S. Using Cardiovascular Systems’ New Technology to Treat Coronary Artery Disease 12/03/13
First cases at: Houston Cardiovascular Associates, Houston North Florida Regional Medical Center, Gainesville, Fla. St. Francis Hospital, Roslyn, N.Y. Dec. 3, 2013- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that its new Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) is being used by physicians across the country to treat coronary artery disease. This follows the company’s recent PMA approval from the U.S. Food and Drug Administration ( FDA ) to market the device as a treatment for severely calcified coronary arteries. “Significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention, and contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used—including a substantially higher occurrence of death and major adverse cardiac events,” said David L. Martin , CSI’s president and chief executive officer. “Severe coronary arterial calcium is...
More >>
Cardiovascular Systems Announces Closing of Common Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 11/26/13
Nov. 26, 2013- Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced the closing of its underwritten registered public offering of an aggregate of 3,000,000 shares of its common stock, including 391,304 shares of common stock sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. All of the shares were sold at a price to the public of $30.00 per share. The aggregate net proceeds to the company from this offering are approximately $84.5 million , after deducting underwriting discounts and commissions and estimated offering expenses. BofA Merrill Lynch acted as the sole book-running manager of the offering. Leerink Swann acted as joint lead manager. William Blair , JMP Securities, Dougherty & Company, Feltl & Company and Wunderlich Securities acted as co-managers. The shares of common stock were sold pursuant to the company's effective shelf registration statement. The offering of these securities was made only by means...
More >>